Cobicistat is a CYP3A inhibitor used to increase the systemic exposure of atazanavir or darunavir in combination with other antiretroviral agents in the treatment of HIV-1 infection. Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV).
- Mechanism
- Curator reviewed
Cobicistat is a mechanism-based inhibitor of cytochrome P450 3A (CYP3A) isoforms. Inhibition of CYP3A-mediated metabolism by cobicistat increases the systemic exposure of CYP3A substrates atazanavir and darunavir and therefore enables increased anti-viral activity at a lower dosage. Cobicistat does not have any anti-HIV activity on its own.
- Primary indication
- Cobicistat is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection.Curator reviewed · 7 structured indications
- Formula / weight
- C40H53N7O5S2 · 776.03 g/mol (avg)
- First approval
- Canada, 2012 · United States, 2012 · European Union, 2016
- Code names
- GS-9350
- Brand names
Resolves to
ZCIGNRJZKPOIKD-CQXVEOKZSA-NSMILESCC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1What you can answer from here — as of June 15, 2026
Which drugs share a target with Cobicistat, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account